I-Mab Stock (NASDAQ:IMAB)
Previous Close
$0.95
52W Range
$0.91 - $2.54
50D Avg
$1.19
200D Avg
$1.52
Market Cap
$75.48M
Avg Vol (3M)
$381.50K
Beta
1.08
Div Yield
-
IMAB Company Profile
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
IMAB Performance
Peer Comparison
Ticker | Company |
---|---|
GRCL | Gracell Biotechnologies Inc. |
NRIX | Nurix Therapeutics, Inc. |
AKRO | Akero Therapeutics, Inc. |
KYMR | Kymera Therapeutics, Inc. |
CGEM | Cullinan Oncology, Inc. |
RVMD | Revolution Medicines, Inc. Warrant |
APLS | Apellis Pharmaceuticals, Inc. |
FHTX | Foghorn Therapeutics Inc. |
BPMC | Blueprint Medicines Corporation |
BGNE | BeiGene, Ltd. |
ERAS | Erasca, Inc. |
LYEL | Lyell Immunopharma, Inc. |
ASND | Ascendis Pharma A/S |
GLUE | Monte Rosa Therapeutics, Inc. |
KRYS | Krystal Biotech, Inc. |
DSGN | Design Therapeutics, Inc. |
IMVT | Immunovant, Inc. |
STTK | Shattuck Labs, Inc. |